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Abstract 
N-acetyltransferase 2 (NAT2) is an important enzyme involved in the metabolism of a 
wide spectrum of naturally occurring xenobiotics, including therapeutic drugs and common 
environmental carcinogens. Extensive polymorphism in NAT2 gives rise to a wide 
interindividual variation in acetylation capacity which influences individual susceptibility to 
various drug-induced adverse reactions and cancers. Striking patterns of geographic 
differentiation have been described for the main slow acetylation variants of the NAT2 gene, 
suggesting the action of natural selection at this locus. In the present study, we took advantage 
of the whole-genome sequence data available from the 1000 Genomes project to investigate 
the global patterns of population genetic differentiation at NAT2 and determine whether they 
are atypical compared to the remaining variation of the genome. The non-synonymous 
substitution c.590G>A (rs1799930) defining the slow NAT2*6 haplotype cluster exhibited an 
unusually low FST value when compared to the genome average (FST = 0.006, P-value = 
0.016). It was pointed out as the most likely target of a homogenizing process of selection 
promoting the same allelic variant in globally distributed populations. The rs1799930 A allele 
has been associated with the slowest acetylation capacity in vivo and its substantial correlation 
with the subsistence strategy adopted by past human populations suggests that it may have 
conferred a selective advantage in populations shifting from foraging to agricultural and 
pastoral activities in the Neolithic period. Results of neutrality tests further supported an 
adaptive evolution of the NAT2 gene through either balancing selection or directional 
selection acting on multiple standing slow-causing variants. 
 
 
 
Introduction 
The human acetylation polymorphism is one of the oldest and best-characterized 
pharmacogenetic traits that underlie interindividual and interethnic differences in response to 
xenobiotics. Acetylation catalised by NAT2 is a major biotransformation pathway for 
aromatic and heterocyclic amines present in the environment and diet, which can either be 
detoxified or bioactivated into metabolites that have the potential to cause toxicity and cancer 
(Butcher et al., 2002; Hein, 2002). From the clinical point of view, NAT2 acetylation is 
increasingly recognized as associated with significant health problems. Many clinically useful 
drugs are excreted by acetylation, some of them being crucial in the treatment of diseases 
representing a worldwide concern, such as tuberculosis, AIDS-related complex diseases, and 
hypertension. The individual acetylation status has proven to be an important determinant of 
both the effectiveness of prescribed medications and the development of adverse drug 
reactions and toxicity during drug treatment (Ladero, 2008; Meisel, 2002). Moreover, 
epidemiological studies have associated the acetylation phenotype with an increased 
susceptibility to various cancers following exposure to aromatic amine carcinogens (Agúndez, 
2008; Hein, 2006; Sanderson et al., 2007; Selinski et al., 2013).  
N-acetylation activity has been investigated in a wide range of populations, leading to a 
phenotype classification of humans in two main categories: fast acetylators, who exhibit the 
so-called ‘wild-type’ or normal acetylation activity, and slow acetylators, characterized by a 
decreased enzyme activity. The proportions of rapid and slow acetylators vary remarkably 
between populations of different ethnic and/or geographic origin (Sabbagh et al., 2011; 
Walker et al., 2009; Weber and Hein, 1985). Depending on the test substrate administered, a 
trimodal, rather than bimodal, distribution can be observed, revealing an additional, 
intermediate phenotype (Cascorbi et al., 1995; Kilbane et al., 1990; Parkin et al., 1997). 
Moreover, recent results suggest that the slow acetylator phenotype is not homogeneous and 
 
 
that several slow acetylator phenotypes may rather exist, resulting from an allelic 
heterogeneity and differential functional effects of the slow acetylation alleles (Ruiz et al., 
2012; Selinski et al., 2013). A refinement in phenotype inference, notably by the 
consideration of an ‘ultra-slow’ acetylator category, is advocated to help identifying new 
clinically relevant associations with one or more of these phenotype subcategories. 
Acetylation polymorphism arises from allelic variations in the NAT2 gene, which result in 
the production of arylamine N-acetyltransferase 2 (NAT2) proteins with variable enzyme 
activity or stability. The NAT2 gene contains two exons with a relatively long intronic region 
of about 8.6 kb. Exon 1 is very short (100 bp) and the entire protein-coding region is 
contained within the 870-bp exon 2. Extensive polymorphism has been described in exon 2, 
with 38 nucleotide variations registered to date (http://nat.mbg.duth.gr/). Of these, four 
common non-synonymous substitutions at positions 191, 341, 590 and 857 are the most 
studied and characterize the major NAT2 slow haplotype clusters (NAT2*14, NAT2*5, 
NAT2*6 and NAT2*7, respectively). Individuals who are homozygous or compound 
heterozygous for two of these low-activity haplotypes are classified as slow acetylators. 
NAT2 acetylation has attracted much research interest in evolutionary biology and several 
population genetic studies have attempted to clarify the role that slow acetylation could have 
played in the adaptation of our species (Fuselli et al., 2007; Luca et al., 2008; Magalon et al., 
2008; Mortensen et al., 2011; Patin et al., 2006; Sabbagh and Darlu, 2006; Sabbagh et al., 
2011). The high prevalence of slow acetylators in humans (well above 50% worldwide) is 
thought to be a consequence of the shift in modes of subsistence and lifestyle in the last 
10,000 years, which triggered significant changes in diet and human exposure to xenobiotic 
compounds. Several surveys of NAT2 sequence variation have indeed provided compelling 
evidence that at least some of the slow-causing variants of NAT2 have been driven to present-
day frequencies through the action of natural selection (Luca et al., 2008; Magalon et al., 
 
 
2008; Mortensen et al., 2011; Patin et al., 2006; Sabbagh et al., 2011). The slow acetylation 
phenotype may thus have been a key adaptation to increase our species fitness in response to 
the transition from foraging to farming. 
Striking patterns of geographic differentiation have been described for the major NAT2 
slow-causing variants (García-Martín, 2008; Sabbagh et al., 2011). The function of NAT2 in 
mediating the interactions between humans and their chemical environment, which varies 
depending on diet and lifestyle, makes it an excellent candidate for population-specific 
selection pressures. Notably, an unusually high level of population differentiation between 
East Asians and other populations (FST values around 0.40) has been described for the 
c.341T>C slow-causing variant (rs1801280), as well as the two linked c.481C>T (rs1799929) 
and c.803A>G (rs1208) nonfunctional SNPs, when compared to an empirical distribution of 
FST computed across a 400-kb region encompassing the whole human NAT gene family 
(Sabbagh et al., 2008). In contrast, the slow 590A variant (rs1799930) was found to occur at 
roughly similar frequencies among widely dispersed populations (Luca et al., 2008; Sabbagh 
et al., 2011). Such a low level of geographic differentiation may rather suggest a 
homogenizing process of natural selection, promoting the same allelic variant in otherwise 
disparate populations (through either directional or balancing selection). Although many 
polymorphisms have been described in other regions of the NAT2 gene (Mortensen et al., 
2011; Patin et al., 2006), limited data exist on the geographic distribution of these variants in 
worldwide populations. 
In this study, we took advantage of the whole-genome sequence data available from the 
1000 Genomes (1KG) project to explore the global patterns of population genetic 
differentiation for the whole set of variants occurring in the entire NAT2 gene sequence (~10 
kb). An outlier approach was used to determine whether the patterns of geographic 
differentiation at this locus were atypical compared to those observed for the remaining 
 
 
variation of the genome. Selection tests based on the site frequency spectrum and extended 
haplotype homozygosity were further applied to determine the possible role of natural 
selection in shaping the atypical patterns observed. 
 
Materials and Methods 
Data retrieval 
Whole-genome variation data generated by the 1KG project in 1,089 unrelated 
individuals was directly downloaded from the 1000 Genomes ftp site 
(ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20110521/), using the phase 1 integrated 
release version 3 of April 2012 (1000 Genomes Project Consortium et al., 2012). The 1,089 
individuals are drawn from 14 different populations in sub-Saharan Africa, Europe, East Asia, 
and the Americas: Yoruba in Ibadan, Nigeria (YRI); Luhya in Webuye, Kenya (LWK); 
people with African ancestry in the Southwest United States (ASW); Utah residents with 
Northern and Western European ancestry (CEU); Tuscans in Italy (TSI); British in England 
and Scotland (GBR); Finnish in Finland (FIN); Iberians in Spain (IBS); Han Chinese in 
Beijing, China (CHB); Southern Han Chinese in China (CHS); Japanese in Tokyo, Japan 
(JPT); people with Mexican ancestry in Los Angeles, California (MXL); Colombians in 
Medellin, Colombia (CLM); and Puerto Ricans in Puerto Rico (PUR). From the obtained vcf 
(variant call format) files, we extracted exclusively the low-coverage VQSR (Variant Quality 
Score Recalibrator method) SNV calls in order to avoid any bias that might result from 
differences between low-coverage whole-genome calls and high-coverage exome SNV calls. 
Indels were not used. Functional annotation of the 36,382,866 SNVs retrieved was performed 
using classification from the dbSNP database (build 137) (http://genome.ucsc.edu/cgi-
bin/hgTables:SNV137.txt). SNVs were assigned to two main classes: genic and nongenic 
 
 
SNVs. Genic SNVs were further classified as intronic, 5’-UTR, 3’-UTR, coding synonymous, 
coding non-synonymous or splice-site. 
 
Population genetic differentiation 
Global levels of population genetic differentiation at NAT2 (chr8:18248755-18258723 in 
the human GRCh37/hg19 assembly) were evaluated by using the fixation index FST (Wright, 
1951) which quantifies the proportion of genetic variance explained by allele frequency 
differences among populations. FST ranges from 0 (for genetically identical populations) to 1 
(for completely differentiated populations). FST scores were computed for all NAT2 SNVs 
occurring with a minor allele frequency (MAF) ≥ 0.05 in at least one of the 14 1KG 
populations, using the BioPerl module PopGen (Stajich et al., 2002). Extreme values of FST 
can result from natural selection but also from nonselective events linked to the demography 
of populations, such as genetic drift. Because such nonselective processes randomly act on the 
genome, they are expected to have the same average effect across the genome, in contrast to 
natural selection, which impacts population differentiation in a locus-specific manner. The 
genome-wide variation data provided by the 1KG project can thus be used to infer the action 
of natural selection by adopting an outlier approach (Kelley et al., 2006). For that purpose, we 
built eight empirical distributions of the FST statistic by considering different subsets of SNVs 
defined according to their physical location and/or functional impact. To obtain distributions 
of likely independent observations, a LD-based pruning procedure was applied to each of 
these eight subsets using Plink (Purcell et al., 2007) with default parameters (pruning based on 
a variance inflation factor of at least 2 within each sliding window of 50 SNVs with a step of 
five SNVs). This resulted in a total of 25,532,386 independent autosomal SNVs included in 
the genome-wide empirical distribution. These numbers are respectively 15,141,160, 
11,282,100, 10,477,050, 24,395, 198,718, 107,644, 146,572, and 1,912 in the nongenic, genic, 
 
 
intronic, 5’UTR, 3’UTR, coding synonymous, coding non-synonymous and splice-site 
distributions. These eight distributions were then used as reference to assess whether the 
patterns of genetic differentiation observed at NAT2 are atypical. Empirical P-values were 
estimated as the proportion of FST scores in the empirical distribution that are either higher 
(diversifying selection) or lower (homogenizing selection) than the value observed at the 
locus of interest. Since FST strongly correlates with heterozygosity (Barreiro et al., 2008; 
Beaumont and Nichols, 1996; Elhaik, 2012), empirical P-values were calculated within bins 
of SNVs grouped according to their global MAF. A total of 27 bins were considered for the 
whole MAF range: 10 bins of size 0.001 for MAF between 0 and 0.01, 9 bins of size 0.01 for 
MAF between 0.01 and 0.10, and 8 bins of size 0.05 for MAF between 0.10 and 0.50.  
 
Selection tests 
To determine whether natural selection has played a role in the unusual patterns of 
geographic differentiation disclosed, we used two complementary approaches based on the 
allele frequency spectrum of segregating sites and on the local haplotype structure. Tajima’s 
D (Tajima, 1989) is a classical neutrality test that compares estimates of the number of 
segregating sites and the average number of pairwise differences between nucleotide 
sequences (π). A zero value of the test statistic D is expected under the null hypothesis of 
selective neutrality, whereas a positive D is taken as indicative of balancing selection and a 
negative one of directional selection. Tajima’s D scores were computed across the whole 
NAT2 coding region by using a sliding window approach with a window size of 1 kb and a 
step size of 100 bp. Statistical significance of the test statistic was assessed using an empirical 
approach. From the genome-wide data available from the 1KG project, we selected a set of 
unlinked noncoding regions expected to be mostly neutrally evolving. A total of 100 
autosomal regions of size 1kb were selected that met the following criteria: (i) to be at least 
 
 
100 kb away from any known or predicted genes or expressed sequence tag or region 
transcribed into mRNA; (ii) to be outside any segmental duplication or region transcribed into 
a long noncoding RNA or conserved noncoding element, as defined in Woolfe et al. (Woolfe 
et al., 2007); (iii) to be distant from each other by at least 100 kb and not in linkage 
disequilibrium (LD) with each other; (iv) to contain a number of SNVs equal to the mean 
number of SNVs included in the 1-kb sliding windows spanning the NAT2 coding region. 
Tajima’s D scores were computed for these 100 regions so as to obtain the null (neutral) 
distribution of the test statistic in each population sample. An empirical P-value was 
estimated at each sliding window position within NAT2 by considering the proportion of 
regions showing a test statistic greater (excess of intermediate-frequency variants) or lower 
(excess of low-frequency variants) than the value observed at that specific position. 
We next used methods based on the extended haplotype homozygosity (EHH) 
measure, i.e. the sharing of identical alleles across relatively long distances by most 
haplotypes in a population sample (Sabeti et al., 2002). We calculated the integrated 
haplotype score (iHS) (Voight et al., 2006) that compares the rate of EHH decay observed for 
both the derived and ancestral allele at each core SNV. An extremely positive or negative 
value at the core SNV provides evidence of positive selection with unusually long haplotypes 
carrying the ancestral or the derived allele, respectively. The raw iHS scores were computed 
for all NAT2 SNVs using the iHS option implemented in the WHAMM! Software (Voight et 
al., 2006), which we slightly modified in order to speed up computation times: thresholds for 
EHH decay were modified from 0.25 to 0.15 and the size of the analyzed region was set to 0.2 
Mb instead of 2.5 Mb. Information on ancestral allele state was obtained from a four-way 
alignment of human, chimpanzee, orangutan and rhesus macaque species, provided by the 
1KG 
 
 
consortium (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/analysis_results/supporting/ance
stral_alignments/). 
We also applied a cross-population test by computing the XP-EHH statistic (Sabeti et al., 
2007) that compares the integrated EHH computed in a test population versus that of a 
reference population. XP-EHH scores were computed using the same EHH decay parameters 
and window size as for iHS. The Yoruba (YRI) sample was used as a reference for samples 
outside Africa, and the Utah residents of European ancestry (CEU) as a reference for African 
samples. 
iHS and XP-EHH scores were also computed for all available SNVs in the 100 neutral 
regions described above, thus providing a reference distribution for each test statistic to 
estimate empirical P-values. Raw scores of iHS and XP-EHH in NAT2 were standardized in 
bins of derived allele frequency (step size of 0.05) using the corresponding distribution of 
each statistic. For both iHS and XP-EHH, we used the phased data provided by the integrated 
Phase 1 release version 3 of the 1KG project (April 2012) and genetic distances were obtained 
from the high density genetic combined map based on 1KG pilot 1 data. 
 
Estimation of the age of the derived allele at rs1799930 
The age of the derived A allele at SNP rs1799930 was estimated using the maximum 
likelihood method implemented in the Estiage software (Génin et al., 2004). This method was 
originally developed to estimate the age of the most recent common ancestor of a rare 
mutation involved in rare disease using microsatellite data. It is based on the length of 
ancestral haplotype segments around the mutation shared by mutation carriers. Haplotypes in 
a 20 kb region centered around rs1799930 were obtained from the phased 1000 Genome data. 
Only SNV were considered and their genetic positions were obtained from the genetic maps 
provided on the Beagle website 
 
 
(http://bochet.gcc.biostat.washington.edu/beagle/genetic_maps/). Only one SNV every 0.01 
cM was kept in the final analysis with Estiage. Age estimates were derived in each population 
separately and a mutation rate of 10-3 per marker per individual per generation was assumed. 
The mutation rate is a key parameter in Estiage that accounts for the fact that the most 
proximal marker where a different allele from the ancestral haplotype is observed in an 
individual might in fact not indicate a recombination but rather a mutation or a genotyping 
error. For SNVs, mutation rates are assumed to be very low in the order of 10-6 but 
genotyping errors can be relatively high. A sensibility analysis was performed to choose the 
value of the mutation rate in a range between 10-6 and 10-2 that gave coherent estimates 
between the different populations and 10-3 was found to be the most plausible value. 
Population allele frequencies at the different markers were estimated on the haplotypes not 
carrying the A alleles at rs1799930. 
 
In-silico prediction of SNV’s functional effects 
The F-SNP method (Lee and Shatkay, 2008) (http://compbio.cs.queensu.ca/F-SNP/) was 
applied to assess the potential functional effect of SNVs. This integrative scoring method 
combines assessments from 16 independent computational tools and databases, using a 
probabilistic framework that takes into account both the certainty of each prediction and the 
reliability of the different tools depending on the physical and functional annotation of the 
specific variant tested. It provides a functional significance (FS) score that quantitatively 
measures the possible deleterious effect of the tested SNV at the splicing, transcriptional, 
translational and post-translational levels. A FS score of 0.5 is considered as the cutoff point 
for predicting a deleterious effect (Lee and Shatkay, 2009). 
 
 
 
Results and Discussion 
Global patterns of population genetic differentiation were examined in the genomic 
region spanning the entire NAT2 gene (~10 kb), using the FST statistic (Wright, 1951) and the 
sequence variation data provided by the 1KG project (1000 Genomes Project Consortium et 
al., 2012). P-values were estimated from empirical distributions built from the background 
genomic variation (see Materials and Methods). We assigned to each genetic variant of the 
NAT2 gene a ‘main P-value’ derived from the genome-wide empirical distribution and a 
‘subset P-value’ derived from the distribution including the subset of SNVs having a similar 
location and/or functional impact than the SNV of interest (i.e., nongenic, intronic, 5’UTR, 
3’UTR, coding synonymous, coding non-synonymous and splice site).  
No SNVs in NAT2 exhibited significantly high FST values compared to the genomic 
background, when considering the global differentiation among the 14 worldwide populations 
from 1KG (all P-values > 0.05). No significant P-values were observed when contrasting East 
Asia to the rest of the world either (data not shown). Although high FST scores were observed 
for the three SNVs c.341T>C (rs1801280), c.481C>T (rs1799929) and c.803A>G (rs1208) in 
this specific pairwise comparison (FST ≈ 0.30), they could not be considered as atypical when 
compared to the rest of the genome (P-values ranging from 0.06 to 0.09). This contrasts with 
previous findings pointing out an atypical pattern of differentiation for these three variants 
when considering HapMap data and only the set of variants located within a 400-kb region 
surrounding the NAT2 gene as a reference distribution (Sabbagh et al., 2008). This difference 
may be due to the different set of populations surveyed or to the more accurate empirical 
distribution used to represent the background genomic variation in the present study. 
In contrast, five NAT2 SNVs exhibited unusually low FST values when compared to the 
genome average, with both main and subset P-values below 0.05 (Figure 1). Four of them 
(rs6984200, rs2087852, rs11996129 and rs1112005) are located in the intronic region of 
 
 
NAT2, while the fifth one (rs1799930) is a non-synonymous substitution defining the NAT2*6 
slow haplotype cluster (c.590G>A resulting in R197Q). Note that the four intronic SNVs are 
in high LD with the rs1799930 variant (r2 ranging from 0.80 to 0.88) (Table 1). They all occur 
at high frequencies in the global human population (within the 0.23-0.26 MAF range). Such 
low levels of population genetic differentiation suggest that at least one of these 
polymorphisms may be subject to balancing or species-wide directional selection, the 
rs1799930 being the most likely target given its gene location and functional impact. 
To determine whether another putative candidate in the genomic region surrounding 
NAT2 might explain the patterns observed, through a significant LD with these variants, we 
extended the analysis to a 600-kb region centered on the human NAT multigene family on 
chromosome 8 (Figure 2). All the variants exhibiting an r2 value above the 0.10 threshold 
with the rs1799930 SNV are located within a 56-kb region (chr8:18229877-18285763 in 
hg19) in the direct vicinity of the NAT2 gene (Figure 2A), making unlikely the involvement of 
another gene in the region. Table 1 provides the list of variants showing a significantly low 
interpopulation FST value for either the main or subset P-value and being in moderate to 
strong LD with the rs1799930 variant (r2 > 0.50). They are all either intergenic (located up to 
~3 kb upstream or 22 kb downstream of the NAT2 gene) or intronic to NAT2. The prediction 
of their functional impact with the F-SNP method revealed high FS scores for some of them 
(FS = 0.50), denoting a potentially deleterious effect by affecting either the transcriptional or 
splicing regulation. However, the highest FS score was observed for the rs1799930 
polymorphism (0.87), which also displayed the lowest subset P-value (P = 0.016; Table 1). 
Altogether, these results point to the rs1799930 polymorphism as the most likely target of 
homogenizing selection in the genomic region surveyed. 
Interestingly, recent evidence suggest that the NAT2*6 haplotype cluster (characterized 
by the rs1799930 A slow-causing allele) is related with the slowest acetylation capacity in 
 
 
vivo, and that the homozygous genotype NAT2*6/*6 thus defines a new category of ‘ultra-
slow’ acetylators (Ruiz et al., 2012; Selinski et al., 2013). Ultra-slow acetylators have about 
30% lower activities of caffeine metabolism compared with other slow acetylators. This is of 
the same order of magnitude than the reduction in enzyme activity between rapid and 
intermediate acetylators (Ruiz et al., 2012). These findings are consistent with a previous 
study by Cascorbi et al. (Cascorbi et al., 1995) that demonstrated a markedly decreased NAT2 
activity in vivo in NAT2*6/*6 compared to NAT2*5/*5 genotypes. Indirect evidence is also 
provided by clinical association studies related to both drug toxicity and cancer risk. Anti-
tuberculosis drug-induced hepatotoxicity risk has been shown to be particularly high in 
carriers of the NAT2*6/*6 genotype (An et al., 2012; Huang et al., 2002; Lee et al., 2010; 
Leiro-Fernandez et al., 2011; Selinski et al., 2014; Teixeira et al., 2011). Similarly, the ultra-
slow genotype, and not the common slow NAT2 genotype, has been significantly associated 
with an increased risk of urinary bladder cancer (Selinski et al., 2013). Altogether, both in 
vivo phenotyping studies and clinical reports suggest that the NAT2*6 variant is likely to be 
associated with a specific acetylation phenotype. This could explain why this particular NAT2 
slow-causing variant, and not another one, may have been a specific target of natural 
selection. 
Although a highly homogenous distribution of the rs1799930 A allele is observed across 
worldwide populations (with a global frequency of 0.246), resulting in an unusually low FST 
value (interpopulation FST = 0.006), a three-fold lower frequency of this allele has been 
reported in hunter-gatherers (~ 0.08) as compared to agriculturalists and pastoralists (~ 0.25) 
in a comprehensive survey of human NAT2 variation including 128 population samples 
classified according to their major subsistence strategy (Sabbagh et al., 2011). This significant 
difference in the frequency of NAT2*6 alleles (P < 0.0001) was identified as the main genetic 
cause of the higher prevalence of the slow acetylation phenotype in populations practicing 
 
 
farming and herding as compared to those mostly relying on hunting and gathering (46% vs 
22%, respectively) (Sabbagh et al., 2011). Given this marked correlation between the 
rs1799930 A allele and the subsistence strategy adopted by past populations in the last 10,000 
years, it has been suggested that this slow-causing allele may have conferred a selective 
advantage in populations shifting from foraging to agricultural and pastoral activities in the 
Neolithic period. New or more concentrated NAT2 substrates introduced in the chemical 
environment of food-producing communities have likely promoted a slower acetylation rate in 
these populations. This hypothesis is further supported by the age estimation of the rs1799930 
A allele in the 1KG populations provided by a maximum-likelihood method implemented in 
the Estiage software (Génin et al., 2004) (Table 2). Our estimations showed that this allele 
started to increase in frequency at similar and recent times in all populations, roughly between 
~1,500 and 6,000 years ago, thereby supporting a global expansion since the emergence of 
agriculture in the Neolithic. Consequently, the markedly low level of population 
differentiation observed at the rs1799930 locus may result from the convergent selection of 
the rs1799930 A allele in agriculturalist and pastoralist populations which are now present in 
most parts of the world. 
Several lines of evidence support the hypothesis that the rs1799930 G>A non-
synonymous substitution (R197Q) has specifically occurred in the human lineage. First, the 
NAT2 197R residue appears to be highly conserved throughout primate evolution, with 100% 
of the orthologous NAT2 sequences generated in 19 distinct simian species harboring an 
arginine (R) at this position (Sabbagh et al., 2013). Second, the 197R position was found to be 
monomorphic in 103 individuals from six great ape species (Pan troglodytes, Pan paniscus, 
Gorilla beringei, Gorilla gorilla, Pongo abellii, Pongo pygmaeus) (Prado-Martinez et al. 
(Prado-Martinez et al., 2013), E.S. Poloni, personal communication), as well as in 28 Rhesus 
monkeys (Macaca mulatta) fully sequenced for the NAT2 gene (A. Sabbagh, personal 
 
 
communication), making the R197Q polymorphism a specific feature of the human lineage. 
The hypothesis of a trans-species polymorphism maintained for several million years, through 
shared balancing selection pressures, seems therefore unlikely. 
Assuming that the rs1799930 A allele has conferred a selective advantage to populations 
shifting from food collection to farming and animal breeding in the Holocene, this could have 
happened either through directional selection or balancing selection. A gene-dose effect has 
been indeed described for this variant, with a significant trend toward a slower acetylation 
capacity in individuals carrying an increasing number of NAT2*6 haplotypes (0, 1 or 2) (Ruiz 
et al., 2012; Selinski et al., 2013). Therefore, heterozygous individuals for this allele display 
an intermediate metabolic phenotype that may have been advantageous if one considers the 
competing needs of both maintaining an efficient detoxification of harmful xenobiotics and 
avoiding the damaging effects of the putative carcinogens that can be activated through NAT2 
acetylation. In an attempt to provide further insights into the evolutionary mechanisms that 
might have driven and maintained the rs1799930 A allele at high frequencies in most human 
populations worldwide, we carried out several tests of selective neutrality based on the allele 
frequency spectrum: Tajima’s D (Tajima, 1989) and haplotype structure: iHS (Voight et al., 
2006) and XP-EHH (Sabeti et al., 2007). An empirical approach using sequence variation data 
from 100 unlinked noncoding regions was adopted to assess statistical significance.  
All iHS and XP-EHH scores computed for the rs1799930 SNV in all individual 
populations from 1KG were not significant at the 0.05 threshold (Table 3). This precludes a 
clear signal of positive selection for this variant as the one expected under a ‘hard sweep 
model’, which assumes the rapid fixation of a single newly arisen advantageous mutation 
(Pritchard et al., 2010). In contrast, we found significant Tajima’s D scores in the 1-kb regions 
encompassing the rs1799930 variant in five population samples: British, Finnish, Tuscans, 
Utah residents of European ancestry and Puerto Ricans (P < 0.05) (Tables 3 and 4). We 
 
 
acknowledge that these results become non-significant when a correction for multiple testing 
is applied, but we also note that the ratio of five significant tests out of 14 is higher than the 
expected 5% proportion of false positives. Non-significant scores, but with P-values getting 
closer to the 5% threshold, were observed in two additional samples (P = 0.07 and P = 0.08 in 
Colombians and Luhya, respectively). Furthermore, although non-significant scores prevent 
rejection of the null hypothesis of selective neutrality, it is noteworthy that all populations 
tested but one (Japanese) gave positive Tajima’s D values, suggesting a trend toward an 
excess of intermediate-frequency variants compatible with the action of balancing selection. 
Such consistent results for populations with different demographic pasts make it unlikely that 
they are due to demography rather than balancing selection. This is also in agreement with 
previous findings demonstrating globally positive and significant Tajima’s D values in 
different continental populations and the absence of any signature of positive selection, as 
detected by EHH-based tests (Fuselli et al., 2007; Luca et al., 2008; Magalon et al., 2008; 
Mortensen et al., 2011). A notable exception concerns the c.341C>T slow-causing variant for 
which a selective sweep was detected in Western and Central Eurasian populations (Patin et 
al., 2006) with the long-range haplotype test (Sabeti et al., 2002). We did not confirm such 
signature of positive selection at this locus in any of the 14 populations from 1KG (both iHS 
and XP-EHH scores not significant at the 0.05 level). No significant scores were observed for 
any of the other slow-causing variants either (c.191G>A, c.341T>C and c.857G>A; data not 
shown). Therefore, patterns of diversity at NAT2 seem compatible with either balancing 
selection or a more complex model of ‘multiallelic’ directional selection where different slow 
variants of NAT2 may have simultaneously become targets of directional selection, thereby 
generating an excess of intermediate-frequency alleles. This would explain why our 
conventional tests of selection based on EHH, more suited to detect classical selective sweeps, 
failed to detect a signature of positive selection at the rs1799930 locus. The signature of 
 
 
selection at this individual position could have been weakened by the global increase in 
frequency of other NAT2 altering mutations. Note, however, that contrary to c.191G>A 
(NAT2*14), c.341T>C (NAT2*5) and c.857G>A (NAT2*7), which mainly cluster in specific 
continental regions (sub-Saharan Africa, Europe and Asia, respectively (Sabbagh et al., 2011), 
the cosmopolitan distribution of the c.590G>A variant (NAT2*6) suggests that it may have 
been positively selected in globally distributed food-producing communities. Finally, the 
hypotheses of balancing and directional selection are not mutually exclusive and multiple 
modes of selection may have operated at the NAT2 locus on a population-specific basis, as 
previously suggested (Mortensen et al., 2011). 
In conclusion, we have described an atypical pattern of geographic differentiation for 
five genetic variants of the NAT2 gene, including the functional rs1799930 SNP defining the 
slow NAT2*6 haplotype series, and four intronic SNPs in high LD with it. An extended 
analysis of a 600-kb region surrounding NAT2 pointed to the rs1799930 polymorphism as the 
most likely target of a homogenizing process of natural selection promoting the same allelic 
variant in most human populations, resulting in an unusually low FST value (FST = 0.006). The 
rs1799930 A allele has been associated with the slowest acetylation capacity in vivo and is 
much more frequent in agriculturalists and pastoralists as compared to hunter-gatherers, 
suggesting it may have been positively selected in food-producing communities which are 
now present in most parts of the world. Neutrality tests based on the allele frequency 
spectrum revealed a trend toward an excess of intermediate-frequency variants at NAT2, 
compatible with either balancing selection or a more complex model of multiallelic 
directional selection. Our findings provide further insights into the functional importance of 
the rs1799930 polymorphism and the role it may have played in human adaptation to 
fluctuating xenobiotic environments. 
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Table 1. List of variants in the 600-kb region surrounding the NAT2 gene with 
significantly low FST values and in high linkage disequilibrium with rs1799930  
SNV Physical 
position on 
chr 8 (hg19) 
Functional 
annotation 
Distance 
from NAT2 
(kb)  
Global 
MAF 
Inter-
population 
FST 
Main            
P-value 
Subset         
P-value 
r2 with 
rs1799930 
Functional 
significance score    
(F-SNP) 
rs11992530 18246133 Intergenic 2.6 0.254 0.006 0.024 0.024 0.80 no known function 
rs4646241 18246696 Intergenic 2.1 0.247 0.007 0.032 0.034 0.83 no known function 
rs4646242 18247449 Intergenic 1.3 0.246 0.006 0.025 0.024 0.84 0.50 
rs4646244 18247718 Intergenic 1.0 0.246 0.006 0.026 0.025 0.84 no known function 
rs6984200 18250317 Intronic 0 0.255 0.007 0.028 0.028 0.80 0.50 
rs2087852 18251926 Intronic 0 0.235 0.007 0.032 0.031 0.86 0.50 
rs11996129 18254575 Intronic 0 0.236 0.005 0.021 0.020 0.85 0.37 
rs1112005 18255876 Intronic 0 0.227 0.005 0.019 0.019 0.88 0.50 
rs1799930 18258103 Coding non-
synonymous 
0 0.246 0.006 0.026 0.016    - 0.87 
rs4646247 18258908 Intergenic 0.2 0.247 0.006 0.025 0.024 0.99 0.50 
rs721398 18259305 Intergenic 0.6 0.244 0.005 0.019 0.020 0.97 no known function 
rs45605031 18260239 Intergenic 1.5 0.248 0.006 0.024 0.026 0.98 no known function 
rs872233 18280686 Intergenic 22.0 0.274 0.007 0.030 0.032 0.76 no known function 
 
 
SNV, single nucleotide variant; MAF, minor allele frequency. Only variants with r2 > 0.50 
with rs1799930 are shown. SNVs located in the NAT2 gene are shaded in grey. A functional 
significance score of 0.5 is considered as the cutoff point for predicting a deleterious effect 
(Lee and Shatkay, 2009). 
  
 
 
Table 2. Estimation of the age of the derived allele at rs1799930 
Population Number of 
carrier 
haplotypes 
Age in 
generations 
[95%CI] 
Age in years [95%CI] 
(1 generation = 20 
years) 
YRI 40 294 [231-376] 5880 [4620-7520] 
LWK 56 139 [111-174] 2780 [2220-3480] 
ASW 34 202 [154-267] 4040 [3080-5340] 
IBS 4 162 [76-356] 3240 [1520-7120] 
TSI 54 129 [104-160] 2580 [2080-3200] 
CEU 50 310 [250-386] 6200 [5000-7720] 
GBR 51 74 [59-93] 1480 [1180-1860] 
FIN 52 77 [61-188] 1540 [1220-3760] 
JPT 43 101 [79-130] 2020 [1580-2600] 
CHB 37 237 [184-308] 4740 [3680-6160] 
CHS 49 203 [164-253] 4060 [3280-5060] 
CLM 27 136 [100-188] 2720 [2000-3760] 
MXL 16 138 [92-223] 2760 [1840-4460] 
PUR 22 173 [124-248] 3460 [2480-4960] 
 
The age of the derived A allele at SNP rs1799930 was estimated using the maximum 
likelihood method implemented in the Estiage software (Génin et al. 2004). YRI: Yoruba 
from Ibadan, Nigeria; LWK: Luhya fromWebuye, Kenya; ASW: people of African ancestry 
from the southwestern United States; IBS: Iberian populations from Spain; TSI: Tuscans from 
Italy; CEU: Utah residents with Northern and Westhern European ancestry; GBR: British 
from England and Scotland; FIN: Finnish from Finland; JPT: Japanese from Tokyo, Japan; 
CHB: Han Chinese from Beijing; CHS: Han Chinese from South China; CLM: Colombians 
from Medellín, Colombia; MXL: people of Mexican ancestry from Los Angeles, California; 
PUR: Puerto Ricans from Puerto Rico. 
 
 
  
 
 
Table 3. Results of selection tests for the NAT2 rs1799930 polymorphism 
 
Significant scores at the 0.05 threshold are shown in bold. YRI: Yoruba from Ibadan, Nigeria; 
LWK: Luhya fromWebuye, Kenya; ASW: people of African ancestry from the southwestern 
United States; IBS: Iberian populations from Spain; TSI: Tuscans from Italy; CEU: Utah 
residents with Northern and Westhern European ancestry; GBR: British from England and 
Scotland; FIN: Finnish from Finland; JPT: Japanese from Tokyo, Japan; CHB: Han Chinese 
from Beijing; CHS: Han Chinese from South China; CLM: Colombians from Medellín, 
Colombia; MXL: people of Mexican ancestry from Los Angeles, California; PUR: Puerto 
Ricans from Puerto Rico. 
* P ≤ 0.10, ** P ≤ 0.05, *** P ≤ 0.01 
a Highest Tajima’s D score observed in the 1-kb sliding windows spanning the rs1799930 
nucleotide position in each individual population. Note that, except in Asians (Japanese and 
both Han Chinese samples), Luhya and African-Americans, these scores also correspond to 
the highest values observed across the whole NAT2 coding region (Table 3). 
 
YRI LWK ASW IBS TSI CEU GBR FIN JPT CHB CHS CLM MXL PUR
iHS 0.18 -0.27 -0.05 -0.82 -0.08 0.17 0.02 -0.19 0.18 -0.11 0.06 0.33 0.09 -0.29
XP-EHH -0.80 0.11 -0.50 1.38 0.54 0.80 0.68 0.42 0.20 0.42 0.02 0.19 0.07 0.13
Tajima's D a 0.33 1.00* 0.60 1.07 2.58** 2.49** 3.28*** 2.67** -0.03 0.91 0.88 1.65* 0.99 1.55**
Africa Europe Asia America
 
 
Table 4. Tajima’s D scores in the 1-kb sliding windows spanning the whole NAT2 coding region 
 
YRI: Yoruba from Ibadan, Nigeria; LWK: Luhya fromWebuye, Kenya; ASW: people of African ancestry from the southwestern United States; 
IBS: Iberian populations from Spain; TSI: Tuscans from Italy; CEU: Utah residents with Northern and Westhern European ancestry; GBR: 
British from England and Scotland; FIN: Finnish from Finland; JPT: Japanese from Tokyo, Japan; CHB: Han Chinese from Beijing; CHS: Han 
YRI LWK ASW IBS TSI CEU GBR FIN JPT CHB CHS CLM MXL PUR
18256555 18257555 none 0.12 -0.37 -0.40 -0.10 0.38 0.21 0.52 -0.45 -0.96 -1.17 -1.41 -0.27 -0.91 -0.23
18256655 18257655 none 0.16 -0.31 -0.32 -0.10 0.38 0.58 0.88 -0.26 -0.96 -1.17 -1.41 0.03 -0.78 0.32
18256755 18257755 c.191G>A 0.55 -0.28 0.04 0.46 0.38 0.78 0.92 0.02 -1.32 -1.05 -1.09 0.08 -0.67 0.23
18256855 18257855 c.191G>A, c.341T>C 1.22* 0.55 0.84 0.67 1.32 1.71 1.85 0.96 -0.61 -0.24 -0.26 0.93 0.09 1.10
18256955 18257955 c.191G>A, c.341T>C 0.94 0.41 0.55 0.67 1.32 1.71 1.85 0.96 -0.61 -0.24 -0.26 0.93 0.09 0.73
18257055 18258055 c.191G>A, c.341T>C 0.69 0.36 0.43 0.67 1.32 1.72 2.46** 1.35 -0.86 -0.24 -0.26 0.91 0.09 0.71
18257155 18258155 c.191G>A, c.341T>C, c.590G>A 0.33 0.82 0.60 0.58 1.57 1.95 3.28*** 2.01* -0.42 0.11 0.18 1.50* 0.13 1.14
18257255 18258255 c.191G>A, c.341T>C, c.590G>A 0.29 0.83 0.60 0.58 2.02 2.49** 3.28*** 2.01* -0.42 0.11 0.18 1.50* 0.13 1.14
18257355 18258355 c.191G>A, c.341T>C, c.590G>A 0.31 0.73 0.29 0.58 2.58** 2.49** 3.28*** 2.01* -0.42 0.11 0.19 1.50* 0.67 1.55**
18257455 18258455 c.191G>A, c.341T>C, c.590G>A, c.857G>A 0.17 1.00* 0.19 1.07 2.06 1.95 2.64*** 2.67** -0.37 0.35 0.78 1.65* 0.96 1.37*
18257555 18258555 c.191G>A, c.341T>C, c.590G>A, c.857G>A -0.007 0.53 0.008 0.70 1.71 1.61 2.23* 2.18* -0.12 0.35 0.78 1.28 0.99 1.13
18257655 18258655 c.191G>A, c.341T>C, c.590G>A, c.857G>A -0.007 0.53 0.008 0.70 1.71 1.61 2.23* 2.18* -0.12 0.35 0.78 1.28 0.99 1.13
18257755 18258755 c.341T>C, c.590G>A, c.857G>A -0.04 0.58 0.06 0.70 2.16* 1.61 2.23* 2.18* -0.12 0.35 0.41 1.28 0.99 1.51*
18257855 18258855 c.590G>A, c.857G>A -0.70 -0.18 -0.62 0.54 0.96 0.87 1.51 1.44 -0.49 0.01 -0.007 0.61 0.03 0.83
18257955 18258955 c.590G>A, c.857G>A -0.42 0.05 -0.47 0.45 1.27 1.21 1.81 1.73 -0.03 0.32 0.39 0.83 0.36 0.97
18258055 18259055 c.590G>A, c.857G>A -0.82 -0.78 -0.88 0.10 0.22 -0.11 0.68 0.62 0.64 0.91 0.88 0.05 -0.22 0.21
18258155 18259155 c.857G>A -0.67 -1.12 -1.05 0.14 -0.17 -0.51 0.29 0.23 0.23 0.70 0.54 -0.23 -0.03 0.004
18258255 18259255 c.857G>A -0.47 -1.01 -0.92 0.14 -0.17 -0.51 0.29 0.23 -0.16 0.70 0.54 -0.23 -0.03 0.004
18258355 18259355 c.857G>A -0.54 -0.90 -0.77 -0.79 -0.35 -0.61 0.12 0.07 0.58 1.42 1.20 -0.13 -0.51 -0.27
Africa Europe Asia America
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Chinese from South China; CLM: Colombians from Medellín, Colombia; MXL: people of 
Mexican ancestry from Los Angeles, California; PUR: Puerto Ricans from Puerto Rico. 
* P ≤ 0.10, ** P ≤ 0.05, *** P ≤ 0.01 
a Genomic position of each 1-kb window on chromosome 8 in the human GRCh37/hg19 
assembly. 
b The four slow causing variants c.191G>A, c.341T>C, c.590G>A and c.857G>A correspond 
to the rs1801279, rs1801280, rs1799930, rs1799931 SNPs, respectively. 
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Figure Captions 
Figure 1. Distribution of -log10 (P-values) of interpopulation FST scores across the human 
NAT2 gene. FST scores were computed among the 14 worldwide populations from the 1000 
Genomes project. P-values were estimated from the lower tail of the empirical distributions. 
(A) Main P-value derived from the genome-wide empirical distribution (including 25,532,386 
SNVs). (B) Subset P-value derived from the empirical distribution including the subset of 
SNVs having a similar location and/or functional impact than the SNV of interest (i.e., 
intronic, 3’UTR, coding synonymous, and coding non-synonymous). The red dotted line 
indicates the 0.05 significance threshold. 
Figure 2. Distribution of -log10 (P-values) of interpopulation FST scores across a 600-kb 
region centered on the human NAT gene family for those variants in linkage 
disequilibrium (r2 > 0.10) with the rs1799930 polymorphism. (A) Level of linkage 
disequilibrium, as measured by the r2 statistic (Hill, 1968), with the rs1799930 genetic 
variant. (B) Main P-value estimated from the lower tail of the genome-wide empirical 
distribution (including 25,532,386 SNVs). (C) Subset P-value estimated from the lower tail 
of the empirical distribution including the subset of SNVs having a similar location and/or 
functional impact than the SNV of interest (i.e., nongenic, intronic, 5’UTR, 3’UTR, coding 
synonymous, coding non-synonymous and splice site). The red dotted line indicates the 0.05 
significance threshold. SNVs are displayed in different colors according to their r2 value with 
rs1799930, ranging from dark blue (r2 = 0.10) to dark red (r2 = 1.0). The rs1799930 
polymorphism is represented as a black triangle. Coding genes and pseudogenes in the 600-kb 
region are represented below as dark grey and light grey boxes, respectively. The genomic 
position (in megabases) on chromosome 8 is indicated on the horizontal axis (human 
GRCh37/hg19 assembly).   
 
 
Figure 3. Distribution of rs1799930 (c.590G>A) allele frequencies in human populations. 
Allele frequency data for the rs1799930 SNP were collected for 146 worldwide samples by 
performing an extensive survey of the literature. Description of samples and retrieved allele 
frequency data are provided in Table S1. Only those samples composed of at least 20 
individuals (N = 105) were represented on the map. Samples are numbered as reported in 
Table S1 (‘sample ID’). Six samples could not be localized on the map because of unspecified 
sampling location (sample 70) or because of divergence between sampling location and 
region of origin (samples 42, 55, 60, 61, and 102); these samples are displayed in a box 
beneath the caption. 
 
